{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:17:56Z","timestamp":1793578676134,"version":"4.5.0"},"reference-count":131,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Shenzhen Key Medical Discipline Construction Fund","award":["SZXK034"],"award-info":[{"award-number":["SZXK034"]}]},{"name":"Shenzhen Fund for Guangdong Provincial Highlevel Clinical Key Specialties","award":["SZGSP012"],"award-info":[{"award-number":["SZGSP012"]}]},{"name":"The Medical Science and Technology Foundation of Guangdong Province","award":["A2023335"],"award-info":[{"award-number":["A2023335"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM201512033"],"award-info":[{"award-number":["SZSM201512033"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Medical Science and Technology Research Project","award":["A2020101"],"award-info":[{"award-number":["A2020101"]}]},{"name":"Shenzhen Healthcare Research Project","award":["SZLY2018015"],"award-info":[{"award-number":["SZLY2018015"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>\n                    Core-binding factor acute myeloid leukemia (CBF-AML) is a subtype of AML characterized by specific genetic rearrangements, including t(8;21) and inv(16), which are associated with a relatively favorable prognosis with relapse rates around 30%. The mutational profiling of CBF-AML is highly heterogeneous in pediatrics, with mutations in the tyrosine kinase pathway (including\n                    <jats:italic toggle=\"yes\">KIT, FLT3<\/jats:italic>\n                    , and\n                    <jats:italic toggle=\"yes\">N\/KRAS<\/jats:italic>\n                    ), epigenetic regulators, cohesin, and additional cytogenetic abnormalities. The identification of high-risk mutations, such as those in\n                    <jats:italic toggle=\"yes\">KIT<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">FLT3<\/jats:italic>\n                    , underscores the need for targeted therapies and highlights the importance of high-throughput sequencing technologies, providing critical insights into the prognosis and informing treatment strategies. Integrating targeted agents with existing treatment protocols has the potential to enhance treatment efficacy and significantly improve patient outcomes. However, CBF-AML presents significant heterogeneity in both pathophysiology and clinical characteristics, with cooperating cytogenetic mutations, leading to difficulties and uncertainties in the prognosis and treatment of CBF-AML in pediatrics. Given the relapse rates and the significant impact of specific mutations on prognosis, there is a critical need for improved risk stratification and personalized treatment approaches in pediatric CBF-AML. Ongoing research and clinical trials focusing on the molecular and genetic profiling of pediatric CBF-AML will be essential for developing more effective and targeted therapies, ultimately improving patient outcomes. This review summarizes the molecular genetics profiling in CBF-AML among pediatrics, targeting its effect and interactions on prognosis and treatment to provide an overview for further research based on mutations among CBF-AML in pediatrics.\n                  <\/jats:p>","DOI":"10.1177\/20406207251330064","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T03:14:29Z","timestamp":1744773269000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2187-9398","authenticated-orcid":false,"given":"Zhilin","family":"Hu","sequence":"first","affiliation":[{"name":"Shantou University Medical College, Shantou, Guangdong, China"},{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guichi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-2685","authenticated-orcid":false,"given":"Sixi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shenzhen Children\u2019s Hospital, Shenzhen, Guangdong 518026, China"},{"name":"Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston 02215, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30186-9"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm4010127"},{"key":"e_1_3_4_4_2","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell LF","year":"2021","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ 2021; 375: n2026.","journal-title":"BMJ"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.181"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007747"},{"key":"e_1_3_4_7_2","author":"Wang S","unstructured":"Wang S, Liu Y, Zhao X, et al. RUNX1-ETO and CBF\u03b2-MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core binding factor-acute myeloid leukemia. Br J Haematol 2024; 205: 552\u2013567.","journal-title":"RUNX1-ETO and CBF\u03b2-MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core binding factor-acute myeloid leukemia"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.675424"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci176311"},{"key":"e_1_3_4_10_2","first-page":"214","article-title":"Relapsed childhood acute myeloid leukemia: prognostic factors and outcomes: experience from a single oncology center","volume":"54","author":"Stankiewicz J","year":"2023","unstructured":"Stankiewicz J, Demidowicz E, Bartoszewicz N, et al. Relapsed childhood acute myeloid leukemia: prognostic factors and outcomes: experience from a single oncology center. Acta Haematol Pol 2023; 54: 214\u2013220.","journal-title":"Acta Haematol Pol"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220962"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1841640"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10965-5"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.153"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1361025"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-688705"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004735"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4630"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571018"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.21037\/tp-20-102"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2022.05.020"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.09.017"},{"key":"e_1_3_4_23_2","article-title":"KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with","volume":"71","author":"Srinivasan S","year":"2024","unstructured":"Srinivasan S, Dhamne C, Patkar N, et al. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1. Pediatr Blood Cancer 2024; 71: e30791.","journal-title":"RUNX1::RUNX1T1. Pediatr Blood Cancer"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.18231\/j.jdpo.2023.051"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131301"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000850080.74457.fa"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001853"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000844900.31768.1d"},{"key":"e_1_3_4_32_2","first-page":"2408","article-title":"Childhood Core Binding Factor (CBF) acute myeloid leukaemia and its association with French American British (FAB) classification","volume":"70","author":"Jabbar N","year":"2020","unstructured":"Jabbar N, Mansoor N, Maqsood S, et al. Childhood Core Binding Factor (CBF) acute myeloid leukaemia and its association with French American British (FAB) classification. J Pak Med Assoc 2020; 70: 2408\u20132411.","journal-title":"J Pak Med Assoc"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000850100.99137.36"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001853"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0566-8"},{"key":"e_1_3_4_36_2","first-page":"25","article-title":"Core binding factor acute myeloid leukemia (CBF-AML) in m\u00e9xico: a single institution experience","volume":"63","author":"Ruiz-Delgado GJ","year":"2011","unstructured":"Ruiz-Delgado GJ, Mac\u00edas-Gallardo J, Lutz-Presno J, et al. Core binding factor acute myeloid leukemia (CBF-AML) in m\u00e9xico: a single institution experience. Rev Invest Clin 2011; 63: 25\u201330.","journal-title":"Rev Invest Clin"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/0009922817732147"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138782"},{"key":"e_1_3_4_39_2","first-page":"52","article-title":"Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia","volume":"40","author":"Wu J","year":"2019","unstructured":"Wu J, Lu AD, Zhang LP, et al. Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi 2019; 40: 52\u201357.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003605"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.21474\/IJAR01\/7977"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.5812\/ijcm.96851"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001034"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13107"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009534"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0158-1"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0086-0"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137424"},{"key":"e_1_3_4_50_2","first-page":"251","article-title":"Adverse prognostic impact of KIT exon 17 mutations despite negative flow cytometric measurable residual disease in pediatric acute myeloid leukemia with","volume":"110","author":"Kato S","year":"2025","unstructured":"Kato S, Tsujimoto S-I, Matsubayashi J, et al. Adverse prognostic impact of KIT exon 17 mutations despite negative flow cytometric measurable residual disease in pediatric acute myeloid leukemia with RUNX1::RUNX1T1. Haematologica 2025; 110: 251\u2013256.","journal-title":"RUNX1::RUNX1T1. Haematologica"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13338"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.783114"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25975"},{"key":"e_1_3_4_54_2","first-page":"2333","article-title":"Gene mutation profile and risk stratification in AML1-ETO-positive acute myeloid leukemia based on next-generation sequencing","volume":"42","author":"Yu G","year":"2019","unstructured":"Yu G, Yin C, Wu F, et al. Gene mutation profile and risk stratification in AML1-ETO-positive acute myeloid leukemia based on next-generation sequencing. Oncol Rep 2019; 42: 2333\u20132344.","journal-title":"Oncol Rep"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0321"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0426-3"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.11.015"},{"key":"e_1_3_4_58_2","first-page":"20","article-title":"Detection of KIT mutations in core binding factor acute myeloid leukemia","volume":"10","author":"Badr P","year":"2018","unstructured":"Badr P, Elsayed GM, Eldin DN, et al. Detection of KIT mutations in core binding factor acute myeloid leukemia. Leuk Res Rep 2018; 10: 20\u201325.","journal-title":"Leuk Res Rep"},{"key":"e_1_3_4_59_2","article-title":"AML-325 prognostic impact of RAS and C-KIT mutations (single vs. multiple) in core-binding factor acute myeloid leukemia (CBF-AML) treated with a fludarabine, cytarabine, and G-CSF (FLAG)\u2013based regimen","volume":"22","author":"Abuasab T","year":"2022","unstructured":"Abuasab T, Senapati J, Kadia T, et al. AML-325 prognostic impact of RAS and C-KIT mutations (single vs. multiple) in core-binding factor acute myeloid leukemia (CBF-AML) treated with a fludarabine, cytarabine, and G-CSF (FLAG)\u2013based regimen. Clin Lymphoma Myeloma Leuk 2022; 22: S235\u2013S236.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.121"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.1947"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.339"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1897"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14274"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0970-x"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.038976"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00586"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1159\/000506194"},{"key":"e_1_3_4_69_2","article-title":"AML-234 prognostic value of FLT3-ITD residual disease in acute myeloid leukemia","volume":"22","author":"Vonk C","year":"2022","unstructured":"Vonk C, Grob T, Sanders M, et al. AML-234 prognostic value of FLT3-ITD residual disease in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2022; 22: S227.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.5045\/br.2020.2020127"},{"key":"e_1_3_4_71_2","article-title":"Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis","volume":"11","author":"Chen W","year":"2016","unstructured":"Chen W, Xie H, Wang H, et al. Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. PLoS One 2016; 11: e0146614.","journal-title":"PLoS One"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.05.006"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100675"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03245"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15492-5"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01054-6"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0129-6"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2023.031"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30108"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113647"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541730"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2021.04.089"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.54393\/fbt.v3i01.33"},{"key":"e_1_3_4_84_2","first-page":"153","article-title":"Clinical and genetic features of 96 children with core binding factor acute myeloid leukemia","volume":"36","author":"Meihui YI","year":"2023","unstructured":"Meihui YI, Min R, Ranran Z, et al. Clinical and genetic features of 96 children with core binding factor acute myeloid leukemia. J Clin Hematol 2023; 36: 153\u2013158.","journal-title":"J Clin Hematol"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.269431"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03475-w"},{"key":"e_1_3_4_87_2","first-page":"20","article-title":"The outcomes of children with acute myeloid leukemia treated in accordance with the AML\u2013MM-2006 protocol","volume":"21","author":"Kalinina II","year":"2022","unstructured":"Kalinina II, Venyov DA, Olshanskaya YuV, et al. The outcomes of children with acute myeloid leukemia treated in accordance with the AML\u2013MM-2006 protocol. Pediatr Hematol Immunopathol 2022; 21: 20\u201335.","journal-title":"Pediatr Hematol Immunopathol"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1919660"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3125.RAS23-B019"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19055"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S191621"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26146"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2190432"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1276896"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106910"},{"key":"e_1_3_4_96_2","article-title":"AML-239 analysis of the genomic heterogeneity of CBF-AML using high-throughput sequencing","volume":"22","author":"Motyko E","year":"2022","unstructured":"Motyko E, Kyriako A, Kus Tova D, et al. AML-239 analysis of the genomic heterogeneity of CBF-AML using high-throughput sequencing. Clin Lymphoma Myeloma Leuk 2022; 22: S227\u2013S228.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22443"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6005"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2081323"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0783-3"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2020.1859169"},{"key":"e_1_3_4_102_2","first-page":"340","article-title":"Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations","volume":"26","author":"Zhou L","year":"2021","unstructured":"Zhou L, An J, Hou C, et al. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations. Hematol Amst Neth 2021; 26: 340\u2013347.","journal-title":"Hematol Amst Neth"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.057901"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124321"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2119-7"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3709"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09846-1"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1683734"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1709836"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31489-9"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26512"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70281-5"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-024-00016-8"},{"key":"e_1_3_4_115_2","first-page":"3925","article-title":"Impact of 9q deletions on the classification in AML","volume":"130","author":"Balk B","year":"2017","unstructured":"Balk B, Stengel A, Meggendorfer M, et al. Impact of 9q deletions on the classification in AML. Blood 2017; 130: 3925.","journal-title":"Blood"},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01996-9"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.3390\/children11050605"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22373"},{"key":"e_1_3_4_119_2","article-title":"Acute myeloid leukemia with t(8;21)(q22;q22) and trisomy 4: a rare occurrence in a female child","volume":"11","author":"Kamran S","year":"2019","unstructured":"Kamran S, Awan SA, Ahmad KN, et al. Acute myeloid leukemia with t(8;21)(q22;q22) and trisomy 4: a rare occurrence in a female child. Cureus 2019; 11: e3885.","journal-title":"Cureus"},{"key":"e_1_3_4_120_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1657400"},{"key":"e_1_3_4_121_2","volume-title":"Obstetric Imaging: Fetal Diagnosis and Care (second Edition)","author":"Armstrong AA","unstructured":"Armstrong AA, Gaw SL, Platt LD. 153 - mosaic trisomies 8, 9, and 16. In: Copel JA, D\u2019Alton ME, Feltovich H, et al. (eds) Obstetric Imaging: Fetal Diagnosis and Care (second Edition). Elsevier, pp. 617-620.e1."},{"key":"e_1_3_4_122_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002673"},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.18203\/2320-6012.ijrms20172464"},{"key":"e_1_3_4_124_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25814"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1661"},{"key":"e_1_3_4_126_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001753"},{"key":"e_1_3_4_127_2","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14764"},{"key":"e_1_3_4_128_2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S100283"},{"key":"e_1_3_4_129_2","first-page":"777","article-title":"Midostaurin\u2014the first targeted therapy drug for patients with acute myeloid leukaemia with FLT3 mutation","volume":"79","author":"Nowicka A","year":"2023","unstructured":"Nowicka A, Sza\u0142ek E, Gil L, et al. Midostaurin\u2014the first targeted therapy drug for patients with acute myeloid leukaemia with FLT3 mutation. Acta Pol Pharm 2023; 79: 777\u2013784.","journal-title":"Acta Pol Pharm"},{"key":"e_1_3_4_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00329-1"},{"key":"e_1_3_4_131_2","doi-asserted-by":"publisher","DOI":"10.1002\/ame2.12076"},{"key":"e_1_3_4_132_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00241"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251330064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251330064","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251330064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:44Z","timestamp":1777591064000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251330064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":131,"alternative-id":["10.1177\/20406207251330064"],"URL":"https:\/\/doi.org\/10.1177\/20406207251330064","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"20406207251330064"}}